Grace Therapeutics, Inc. Stock-Based Compensation
Grace Therapeutics, Inc. (GRCE) reported Stock-Based Compensation of $105.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $105.00K, a 65.23% decline year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $182.00K, a 40.00% increase year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $108.00K, a 32.50% decline year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $206.00K, a 1.98% increase year-over-year.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2026 was $798.00K, a 9.32% increase from fiscal 2025.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $730.00K, a 20.04% decline from fiscal 2024.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $913.00K, a 49.59% decline from fiscal 2023.
- Grace Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.81M, a 35.45% increase from fiscal 2022.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $105.00K 10-Q · filed 2026-08-13 | $287.00K derived: sum of 2 quarters · filed 2026-08-13 | $395.00K derived: sum of 3 quarters · filed 2026-08-13 | $601.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $290.00K derived: sum of 2 quarters · filed 2026-06-18 | $496.00K derived: sum of 3 quarters · filed 2026-06-18 | $798.00K 10-K · filed 2026-06-18 |
| 2025-12-31 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $314.00K derived: sum of 2 quarters · filed 2026-02-12 | $616.00K 10-Q · filed 2026-02-12 | $746.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $508.00K 10-Q · filed 2025-11-13 | $638.00K derived: sum of 3 quarters · filed 2026-08-13 | $798.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $302.00K 10-Q · filed 2026-08-13 | $432.00K derived: sum of 2 quarters · filed 2026-08-13 | $592.00K derived: sum of 3 quarters · filed 2026-08-13 | $794.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | $290.00K derived: sum of 2 quarters · filed 2026-06-18 | $492.00K derived: sum of 3 quarters · filed 2026-06-18 | $730.00K 10-K · filed 2026-06-18 |
| 2024-12-31 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $362.00K derived: sum of 2 quarters · filed 2026-02-12 | $600.00K 10-Q · filed 2026-02-12 | $829.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $440.00K 10-Q · filed 2025-11-13 | $669.00K derived: sum of 3 quarters · filed 2025-11-13 | $995.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $238.00K 10-Q · filed 2025-08-12 | $467.00K derived: sum of 2 quarters · filed 2025-08-12 | $793.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.07M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $555.00K derived: sum of 2 quarters · filed 2025-06-23 | $835.00K derived: sum of 3 quarters · filed 2025-06-23 | $913.00K 10-K · filed 2025-06-23 |
| 2023-12-31 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $606.00K derived: sum of 2 quarters · filed 2025-02-13 | $684.00K 10-Q · filed 2025-02-13 | $1.01M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | $358.00K 10-Q · filed 2024-11-13 | $680.00K derived: sum of 3 quarters · filed 2024-11-13 | $1.12M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $78.00K 10-Q · filed 2024-08-09 | $400.00K derived: sum of 2 quarters · filed 2024-08-09 | $843.00K derived: sum of 3 quarters · filed 2024-08-09 | $1.43M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $765.00K derived: sum of 2 quarters · filed 2024-06-21 | $1.35M derived: sum of 3 quarters · filed 2024-06-21 | $1.81M 10-K · filed 2024-06-21 |
| 2022-12-31 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | $1.02M derived: sum of 2 quarters · filed 2024-02-12 | $1.49M 10-Q · filed 2024-02-12 | $2.10M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | $582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $1.05M 10-Q · filed 2023-11-13 | $1.66M derived: sum of 3 quarters · filed 2023-11-13 | $2.12M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $464.00K 10-Q · filed 2023-08-11 | $1.08M derived: sum of 2 quarters · filed 2023-08-11 | $1.53M derived: sum of 3 quarters · filed 2023-08-11 | $1.65M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | $1.07M derived: sum of 2 quarters · filed 2023-06-23 | $1.18M derived: sum of 3 quarters · filed 2023-06-23 | $1.34M 10-K · filed 2023-06-23 |
| 2021-12-31 | $454.00K 10-Q · filed 2022-02-14 | $568.00K derived: sum of 2 quarters · filed 2022-02-14 | $721.00K 10-Q · filed 2023-02-14 | $892.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-09-30 | $114.00K 10-Q · filed 2021-11-10 | $267.00K 10-Q · filed 2022-11-14 | $438.00K derived: sum of 3 quarters · filed 2022-08-11 | $408.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $153.00K 10-Q · filed 2022-08-11 | $324.00K derived: sum of 2 quarters · filed 2022-08-11 | $294.00K derived: sum of 3 quarters · filed 2022-08-11 | $695.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | $141.00K derived: sum of 2 quarters · filed 2022-06-21 | $542.00K derived: sum of 3 quarters · filed 2022-06-21 | $1.17M 10-K · filed 2022-06-21 |
| 2020-12-31 | -$30.00K 10-Q · filed 2022-02-14 | $371.00K derived: sum of 2 quarters · filed 2022-02-14 | $1.00M 10-Q · filed 2022-02-14 | $2.96M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $401.00K 10-Q · filed 2021-11-10 | $1.03M 10-Q · filed 2021-11-10 | $2.99M derived: sum of 3 quarters · filed 2021-11-10 | $3.60M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $632.00K 10-Q · filed 2021-08-12 | $2.58M derived: sum of 2 quarters · filed 2021-08-12 | $3.20M derived: sum of 3 quarters · filed 2021-08-12 | $3.85M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.95M 10-K · filed 2020-06-29 | $2.56M derived: sum of 2 quarters · filed 2021-02-09 | $3.21M derived: sum of 3 quarters · filed 2021-02-09 | $1.95M 10-K · filed 2021-06-22 |
| 2019-12-31 | $611.00K 10-Q · filed 2021-02-09 | $1.26M derived: sum of 2 quarters · filed 2021-02-09 | $1.51M 10-Q · filed 2021-02-09 | $2.29M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-09-30 | $650.00K 10-Q · filed 2020-11-16 | $900.00K 10-Q · filed 2020-11-16 | $1.68M derived: sum of 3 quarters · filed 2020-11-16 | |
| 2019-06-30 | $250.00K 10-Q · filed 2020-08-13 | $1.03M derived: sum of 2 quarters · filed 2020-08-13 | ||
| 2019-03-31 | $777.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |